Mark Shaefer
Overview
Explore the profile of Mark Shaefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Overton E, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al.
Lancet
. 2020 Dec;
396(10267):1994-2005.
PMID: 33308425
Background: Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing,...
2.
Murray M, Antela A, Mills A, Huang J, Jager H, Bernal E, et al.
AIDS Behav
. 2020 May;
24(12):3533-3544.
PMID: 32447500
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized...
3.
Mantsios A, Murray M, Karver T, Davis W, Margolis D, Kumar P, et al.
Cult Health Sex
. 2020 May;
23(8):1066-1078.
PMID: 32436478
Long-acting injectable antiretroviral therapy has been shown to be non-inferior to daily oral antiretroviral therapy in clinical trials and may soon become part of clinical care. While most trial participants...
4.
Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, et al.
Hum Immunol
. 2020 Mar;
81(6):300-304.
PMID: 32173028
Abacavir hypersensitivity syndrome (ABC HSS) is strongly associated with carriage of human leukocyte antigen (HLA)-B*57:01, which has a 100% negative predictive value for the development of ABC HSS. However, 45%...
5.
Nan C, Shaefer M, Urbaityte R, Oyee J, Hopking J, Ragone L, et al.
Open Forum Infect Dis
. 2018 May;
5(5):ofy086.
PMID: 29766019
Background: Some observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use and myocardial infarction (MI), whereas others have not. Methods: This pooled analysis of...
6.
Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, et al.
Clin Pharmacol Ther
. 2017 Nov;
103(3):402-408.
PMID: 29150845
In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. An open-label, four-way crossover study was conducted in healthy...
7.
Cohen C, DeJesus E, LaMarca A, Young B, Yau L, Patel L, et al.
HIV Clin Trials
. 2010 Dec;
11(5):239-47.
PMID: 21126954
Purpose: ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV,...
8.
Watson M, Patel L, Ha B, Wannamaker P, Cuffe R, Shaefer M
AIDS Patient Care STDS
. 2009 Oct;
23(11):957-63.
PMID: 19839743
Screening for HLA-B 5701 reduces the risk of developing an abacavir hypersensitivity reaction (ABC HSR) and is recommended in all patients before initiating highly active antiretroviral therapy (HAART) with abacavir....
9.
Young B, Squires K, Patel P, DeJesus E, Bellos N, Berger D, et al.
AIDS
. 2008 Aug;
22(13):1673-5.
PMID: 18670229
A hypersensitivity reaction is associated with abacavir in approximately 2-8% of exposed patients. The frequency of the HLA-B*5701 allele varies across racial groups and significantly correlates with risk of hypersensitivity....
10.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al.
Clin Infect Dis
. 2008 May;
46(7):1111-8.
PMID: 18444831
Background: Although the human leukocyte antigen (HLA)-B*5701 is highly associated with a hypersensitivity reaction (HSR) to abacavir (ABC), variable sensitivities have been reported when clinical data alone have been used...